参考文献/References:
[1] Schuppan D, Afdhal NH. Liver cirrhosis[J]. Lancet, 2008, 371: 838- 51.
[2] 原姗姗, 韩国宏, 樊代明. TIPS治疗门静脉高压并发症预后评价的现状[J]. 介入放射学杂志, 2011, 20: 245- 248.
[3] Vorobioff JD, Groszmann RJ. Prevention of portal hypertension: from variceal development to clinical decompensation[J]. Hepatology, 2015, 61: 375- 381.
[4] Blomme B, Van Steenkiste C, Vanhuysse J, et al. Impact of elevation of total bilirubin level and etiology of the liver disease on serum N- glycosylation patterns in mice and humans[J]. Am J Physiol Gastrointest Liver Physiol, 2010, 298: G615- G624.
[5] Mookerjee RP, Mehta G, Balasubramaniyan V, et al. Hepatic dimethylarginine- dimethylaminohydrolase- 1 is reduced in cirrhosis and is a target for therapy in portal hypertension[J]. J Hepatol, 2015, 62: 325- 331.
[6] Van Steenkiste C, Ribera J, Geerts A, et al. Inhibition of placental growth factor activity reduces the severity of fibrosis, inflammation, and portal hypertension in cirrhotic mice[J]. Hepatology, 2011, 53: 1629- 1640.
[7] Altrock E, Sens C, Wuerfel C, et al. Inhibition of fibronectin deposition improves experimental liver fibrosis[J]. J Hepatol, 2015, 62: 625- 633.
[8] Iwakiri Y. Pathophysiology of portal hypertension[J]. Clin Liver Dis, 2014, 18: 281- 291.
[9] Sanyal AJ, Bosch J, Blei A, et al. Portal hypertension and its complications[J]. Gastroenterology, 2008, 134: 1715- 1728.
[10] 陈 皓, 杨卫平, 李宏为. 肝移植时代传统外科手术在肝硬化门静脉高压症中的治疗地位[J]. 外科理论与实践, 2016, 21: 372- 374.
[11] 徐 克, 韩国宏. 正确认识经颈静脉肝内门体分流术治疗肝硬化门静脉高压并发症的地位[J]. 中华肝脏病杂志, 2011, 19: 481- 482.
[12] 薛 挥, 李培杰, 李伟之, 等. 经颈静脉肝内门体分流术的并发症及其防治[J]. 临床肝胆病杂志, 2016, 32: 238- 241.
[13] 曹 青, 彭小刚, 洪 葵. 诺贝尔生理或医学奖:基因靶向技术和人类疾病小鼠模型[J]. 江西医学, 2012, 47: 414- 416.
[14] Novo E, Cannito S, Paternostro C, et al. Cellular and molecular mechanisms in liver fibrogenesis[J]. Arch Biochem Biophys,2014, 15: 20- 37.
[15] 李生财, 李 彤. 肝纤维化动物模型的造模原理及应用[J]. 中医药学刊, 2016, 24: 2267- 2268.
[16] Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease[J]. Nat Med, 2012, 18: 1028- 1040.
[17] Schwabl P, Payer BA, Grahovac J, et al. Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non- cirrhotic portal hypertensive rats[J]. J Hepatol, 2014, 60: 1135- 1142.
相似文献/References:
[1]李松蔚,李迎春,闫 东,等.Fluency覆膜支架行TIPS术后支架狭窄原因分析[J].介入放射学杂志,2015,(12):1047.
LI Song- wei,LI Ying- chun,YAN Dong,et al.Transjugular intrahepatic portosystemic shunt with Fluency covered stent: analysis of the causes of stent stenosis[J].journal interventional radiology,2015,(03):1047.
[2]李兆南,徐燕能,张向琼,等.Y形通道治疗经颈静脉肝内门体分流术后支架分流道梗阻的初步研究 [J].介入放射学杂志,2017,(09):779.
LI Zhaonan,XU Yanneng,ZHANG Xiangqiong,et al.Treatment of post- TIPS stent shunt obstruction by using Y- shaped channel technique: a preliminary study[J].journal interventional radiology,2017,(03):779.
[3]杨胜利,赖林强,宋晶晶,等.裸支架联合覆膜支架行经颈静脉肝内门体静脉分流术治疗门静脉高压症远期效果[J].介入放射学杂志,2024,33(03):295.
YANG Shengli,LAI Linqiang,SONG Jingjing,et al.TIPS with bare stents and covered stents for the treatment of portal hypertension: analysis of its long-term efficacy[J].journal interventional radiology,2024,33(03):295.